Xintela to develop stem cell therapy for difficult-to-heal wounds

Xintela, together with Professor Folke Sjöberg and his team at The Burn Center at Linköping University Hospital, showed that XSTEM provides excellent healing of wounds in a pig model and that the newly formed skin tissue closely resembles normal skin. XSTEM also showed less scarring compared to transplanted skin cells. Xintela is now planning for clinical studies together with the Linköping team.

- Wound healing is an exciting indication for our stem cell product XSTEM. The medical need is very high and we see a large and attractive market in an area that consumes significant healthcare resources. We can quickly enter the market with a wound healing XSTEM product because clinical studies in wound healing can be completed in a relatively short time, says Xintela's CEO Evy Lundgren-Åkerlund.

Professor Folke Sjöberg, who is very well known internationally for his burn research, and who has together with his research team has also shown success in other wound healing areas, particularly in difficult-to-heal wounds, where new methodology and new research models have been developed, says:

- Difficult-to-heal wounds, also called chronic wounds, are a comprehensive medical problem that cause a lot of pain and suffering for patients and we currently lack good treatment methods. Difficult-to-heal wounds usually have several underlying causes and therefore Xintela's XSTEM product, which can potentially have several different wound healing functions, is extremely interesting. We are very impressed with the healing potential that we have seen so far with Xintela's stem cell product XSTEM and are therefore very much looking forward to treating patients with XSTEM in clinical trials.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication at 11:40 CET on the 20th of May, 2021.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: [email protected]
Medicon Village
223 81 Lund, Sweden
www.xintela.se 

About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, [email protected].

The following documents can be retrieved from beQuoted
2021-05-20-Xintela-to-develop-stem-cell-therapy-for-difficul.pdf

If you want to open the text in your webbrowser click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected]

beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.

Vi hoppas att Du uppskattar denna service.